Nemluvio (nemolizumab)

pCPA File Number: 23482

Negotiation Status:

Under consideration for negotiation

Indication(s):

For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.

Sponsor/Manufacturer:

Galderma Canada Inc.

CDA-AMC Project Number:

SR0869-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable